You are here: Industry Insights > Ankylosing Spondylitis

News List

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis prnasia
January 19, 2022
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondylitis.
Akeso's Il-17A Monoclonal Antibody (Gumokimab) Completion Of Patient Enrollment In Phase II Clinical Trial For The Treatment Of Ankylosing Spondylitis prnasia
December 29, 2021
Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed.
Henlius Adalimumab Biosimilar Approved by NMPA prnasia
December 09, 2020
Shanghai Henlius Biotech, Inc. announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis ...
IBI303 results for Ankylosing Spondylitis published in "The Lancet Rheumatology” biospectrumasia
September 03, 2019
The first time a highly-regarded top-tier medical journal has featured the major phase III clinical trial results of a China-developed biosimilar
Eli Lilly's Taltz pads case for a shot at Novartis' Cosentyx in ankylosing spondylitis fiercepharma
June 29, 2018
Eli Lilly’s Taltz is already up against Novartis’ immunology blockbuster Cosentyx in psoriasis and psoriatic arthritis. Now, Lilly looks poised to challenge the Swiss drugmaker in a third indication, too.